Alnylam Pharmaceuticals Inc.

04/15/2019 | Press release | Distributed by Public on 04/15/2019 05:17

Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label[...]